Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | MRD: a promising biomarker in multiple myeloma

Jill Corre • 13 May 2022
COMy 2022
Multiple Myeloma
CASSIOPEIA MIDAS

In this video, Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, discusses the role of measurable residual disease (MRD) as a promising biomarker in multiple myeloma, and further highlights clinical trials supporting the use of MRD. Dr Corre emphasizes the improved progression-free survival (PFS) observed in patients who achieve MRD negativity, and further highlights clinical trials investigating MRD in myeloma, including the Cassiopeia trial (NCT02541383) and the MIDAS trial (NCT04934475), and also discusses the importance of post-induction timepoints. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Jill Corre

Updates in the genomics of SMM & multiple myeloma
Francesco Maura et al. • 15 Apr 2023
1:57
Using molecular abnormalities for risk stratification in multiple myeloma at the time of diagnosis
Jill Corre • 12 May 2023
2:20
Novel technologies and the prognostic value of identifying subclones in myeloma
Jill Corre • 12 May 2023
2:02
The impact of heterogeneity on outcomes in multiple myeloma
Jill Corre • 30 Aug 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals